TY - JOUR
T1 - Polymer-based or polymer-free stents in patients at high bleeding risk
AU - ONYX ONE Investigators
AU - Windecker, S.
AU - Latib, A.
AU - Kedhi, E.
AU - Kirtane, A. J.
AU - Kandzari, D. E.
AU - Mehran, R.
AU - Price, M. J.
AU - Abizaid, A.
AU - Simon, D. I.
AU - Worthley, S. G.
AU - Zaman, A.
AU - Hudec, M.
AU - Poliacikova, P.
AU - Abdul Ghapar, A. K.
AU - Selvaraj, K.
AU - Petrov, I.
AU - Mylotte, D.
AU - Pinar, E.
AU - Moreno, R.
AU - Fabbiocchi, F.
AU - Pasupati, S.
AU - Kim, H. S.
AU - Aminian, A.
AU - Tie, C.
AU - Wlodarczak, A.
AU - Hur, S. H.
AU - Marx, S. O.
AU - Jankovic, I.
AU - Brar, S.
AU - Bousquette, L.
AU - Liu, M.
AU - Stone, G. W.
N1 - Publisher Copyright:
Copyright © 2020 Massachusetts Medical Society.
PY - 2020/3/26
Y1 - 2020/3/26
N2 - BACKGROUND Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited. METHODS In an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk. After PCI, patients were treated with 1 month of dual antiplatelet therapy, followed by single antiplatelet therapy. The primary outcome was a safety composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year. The principal secondary outcome was target-lesion failure, an effectiveness composite of death from cardiac causes, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization. Both outcomes were powered for noninferiority. RESULTS A total of 1996 patients at high bleeding risk were randomly assigned in a 1:1 ratio to receive zotarolimus-eluting stents (1003 patients) or polymer-free drugcoated stents (993 patients). At 1 year, the primary outcome was observed in 169 of 988 patients (17.1%) in the zotarolimus-eluting stent group and in 164 of 969 (16.9%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% confidence interval [CI], 3.5; noninferiority margin, 4.1; P = 0.01 for noninferiority). The principal secondary outcome was observed in 174 patients (17.6%) in the zotarolimus-eluting stent group and in 169 (17.4%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% CI, 3.5; noninferiority margin, 4.4; P = 0.007 for noninferiority). CONCLUSIONS Among patients at high bleeding risk who received 1 month of dual antiplatelet therapy after PCI, use of polymer-based zotarolimus-eluting stents was noninferior to use of polymer-free drug-coated stents with regard to safety and effectiveness composite outcomes.
AB - BACKGROUND Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal stents in patients at high bleeding risk who undergo percutaneous coronary intervention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on the use of polymer-based drug-eluting stents, as compared with polymer-free drug-coated stents, in such patients are limited. METHODS In an international, randomized, single-blind trial, we compared polymer-based zotarolimus-eluting stents with polymer-free umirolimus-coated stents in patients at high bleeding risk. After PCI, patients were treated with 1 month of dual antiplatelet therapy, followed by single antiplatelet therapy. The primary outcome was a safety composite of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year. The principal secondary outcome was target-lesion failure, an effectiveness composite of death from cardiac causes, target-vessel myocardial infarction, or clinically indicated target-lesion revascularization. Both outcomes were powered for noninferiority. RESULTS A total of 1996 patients at high bleeding risk were randomly assigned in a 1:1 ratio to receive zotarolimus-eluting stents (1003 patients) or polymer-free drugcoated stents (993 patients). At 1 year, the primary outcome was observed in 169 of 988 patients (17.1%) in the zotarolimus-eluting stent group and in 164 of 969 (16.9%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% confidence interval [CI], 3.5; noninferiority margin, 4.1; P = 0.01 for noninferiority). The principal secondary outcome was observed in 174 patients (17.6%) in the zotarolimus-eluting stent group and in 169 (17.4%) in the polymer-free drug-coated stent group (risk difference, 0.2 percentage points; upper boundary of the one-sided 97.5% CI, 3.5; noninferiority margin, 4.4; P = 0.007 for noninferiority). CONCLUSIONS Among patients at high bleeding risk who received 1 month of dual antiplatelet therapy after PCI, use of polymer-based zotarolimus-eluting stents was noninferior to use of polymer-free drug-coated stents with regard to safety and effectiveness composite outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85082394370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082394370&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1910021
DO - 10.1056/NEJMoa1910021
M3 - Article
C2 - 32050061
AN - SCOPUS:85082394370
SN - 0028-4793
VL - 382
SP - 1208
EP - 1218
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 13
ER -